CompanyGraph
At a glance
- Depends onUpstream position: supplies 6 industries, depends on 3
- ScaleMarket cap is $11.36B, above the global median of $1.18B
- FinancialsAltman Z-Score 12.07: safe zone
- Interpretations5 currently firing — 1 · 4
Sign in to view price data.
Sign inWhat the company actually pays, and whether its own cash supports it.
Dividends view
Yield
0.44%Above 5Y avg (0.44%)
Annual Rate
USD 0.32Paid quarterly
Payout Ratio
27.6%Sustainable
Paying Dividends
14 yr
Last Ex-Dividend
Aug 24, 2026
Last Payment
Sep 4, 2026
Screen for this company's dividend patterns
Find other companies where the same dividend readings fire.
Long Dividend Streak With Three-Year FCF Coverage
→dividend consistency
dividend coverage and payment stability
ratio cashflow fcf conversion
1 interpretation currently present — each is a set of fired observations whose alignment reads as one structural pattern. Click an observation to see the numbers behind it.
Screen for these patternsHow does this company return capital?
Long Dividend Streak With Three-Year FCF Coverage
Years of uninterrupted dividends, covered by free cash flow on a three-year average.
Reads
An interpretation is present only while every observation it reads stays fired (score ≥ 70). It describes what the aligned readings show — never a verdict, never a prediction.
The reported statements, read against the company's own industry.
Financials view
Market Capitalization
11.36BUSDvs all stocks (USD)
Trailing P/E
62.47xvs Biotechnology peers
Revenue (TTM)
1.22BUSDvs all stocks (USD)
Profit Margin
14.97%vs Biotechnology peers
Beta
1.28xvs all stocks
52-Week Change
32.53%vs all stocks
Forward Annual Dividend Yield
0.44%vs all stocks
Market Capitalization
11.36BUSDvs all stocks (USD)
Enterprise Value
11.39BUSDvs all stocks (USD)
Trailing P/E
62.47xvs Biotechnology peers
Forward P/E
31.28xvs Biotechnology peers
PEG Ratio
0.4603xvs Biotechnology peers
Price to Sales (TTM)
9.35xvs Biotechnology peers
Price to Book (MRQ)
5.44xvs Biotechnology peers
Enterprise to Revenue
9.37xvs Biotechnology peers
Enterprise to EBITDA
34.09xvs Biotechnology peers
Gross Margin
66.88%vs Biotechnology peers
Profit Margin
14.97%vs Biotechnology peers
Operating Margin
27.87%vs Biotechnology peers
Return on Assets (TTM)
6.67%vs Biotechnology peers
Return on Equity (TTM)
9.03%vs Biotechnology peers
Revenue (TTM)
1.22BUSDvs all stocks (USD)
Revenue per Share (TTM)
7.79USDUpdated Aug 28, 2026Quarterly Revenue Growth
1.30%vs Biotechnology peers
Gross Profit (TTM)
804.88MUSDvs all stocks (USD)
EBITDA (TTM)
257.15MUSDvs all stocks (USD)
Net Income (TTM)
181.84MUSDvs all stocks (USD)
Quarterly Earnings Growth (YoY)
-1.51%vs Biotechnology peers
Operating Cash Flow (TTM)
292.07MUSDvs all stocks (USD)
Levered Free Cash Flow (TTM)
229.65MUSDvs all stocks (USD)
Forward Annual Dividend Rate
0.3200USDUpdated Aug 28, 2026Forward Annual Dividend Yield
0.44%vs all stocks
Trailing Annual Dividend Rate
0.3200USDUpdated Aug 28, 2026Trailing Annual Dividend Yield
0.44%vs all stocks
5-Year Average Dividend Yield
0.44%vs all stocks
Payout Ratio
27.59%vs Biotechnology peers
Minority Interest (Equity)
0.00USDFY2025 · Jun 30, 2025Revenue
1.22BUSDFY2025 · Jun 30, 2025Cost of Goods Sold
429.36MUSDFY2025 · Jun 30, 2025Gross Profit
790.27MUSDFY2025 · Jun 30, 2025Operating Income
242.80MUSDvs all stocks (USD)
Pre-tax Income
98.46MUSDFY2025 · Jun 30, 2025Income Tax Expense
25.06MUSDFY2025 · Jun 30, 2025Net Income
73.40MUSDFY2025 · Jun 30, 2025EBIT
106.97MUSDFY2025 · Jun 30, 2025EBITDA (Income Statement)
357.57MUSDFY2025 · Jun 30, 2025Research & Development
99.50MUSDFY2025 · Jun 30, 2025Selling, General & Administrative
415.10MUSDFY2025 · Jun 30, 2025Non-operating Interest Income
3.89MUSDFY2025 · Jun 30, 2025Non-operating Interest Expense
8.51MUSDFY2025 · Jun 30, 2025EPS (Basic)
0.4700USDFY2025 · Jun 30, 2025EPS (Diluted)
0.4600USDFY2025 · Jun 30, 2025Basic Shares Outstanding
157.52MSharesFY2025 · Jun 30, 2025Diluted Shares Outstanding
157.52MSharesFY2025 · Jun 30, 2025Net Income from Continuing Operations
73.40MUSDFY2025 · Jun 30, 2025Minority Interests (P&L)
0.00USDFY2025 · Jun 30, 2025Preferred Stock Dividends
37.00KUSDFY2025 · Jun 30, 2025Operating Cash Flow
185.64MUSDFY2025 · Jun 30, 2025Free Cash Flow
154.64MUSDFY2025 · Jun 30, 2025Cash & Cash Equivalents (End of Period)
162.19MUSDFY2025 · Jun 30, 2025Income Tax Paid
74.36MUSDFY2025 · Jun 30, 2025Interest Paid
18.95MUSDFY2025 · Jun 30, 2025Starting Profit (CF Statement)
73.40MUSDFY2025 · Jun 30, 2025Depreciation & Amortization
109.90MUSDFY2025 · Jun 30, 2025Deferred Taxes (CF)
-51.11MUSDFY2025 · Jun 30, 2025Stock-based Compensation
40.83MUSDFY2025 · Jun 30, 2025Other Non-cash Items
2.11MUSDFY2025 · Jun 30, 2025Change in Accounts Receivable (CF)
42.60MUSDFY2025 · Jun 30, 2025Change in Accounts Payable (CF)
-13.95MUSDFY2025 · Jun 30, 2025Change in Other Assets/Liabilities
-18.14MUSDFY2025 · Jun 30, 2025Capital Expenditures
-31.01MUSDFY2025 · Jun 30, 2025Net Acquisitions
-15.00MUSDFY2025 · Jun 30, 2025Purchase of Investments
0.00USDFY2025 · Jun 30, 2025Sale of Investments
1.08MUSDFY2025 · Jun 30, 2025Other Investing Activity
2.45MUSDFY2025 · Jun 30, 2025Net Investing Cash Flow
-42.47MUSDFY2025 · Jun 30, 2025Long-term Debt Issuance
104.00MUSDFY2025 · Jun 30, 2025Long-term Debt Payments
-77.00MUSDFY2025 · Jun 30, 2025Common Stock Repurchase
-275.73MUSDFY2025 · Jun 30, 2025Common Dividends Paid
-50.39MUSDFY2025 · Jun 30, 2025Other Financing Charges
-6.52MUSDFY2025 · Jun 30, 2025Net Financing Cash Flow
-305.64MUSDFY2025 · Jun 30, 2025Shares Outstanding
156.52MSharesUpdated Aug 28, 2026Float Shares
156.17MSharesUpdated Aug 28, 2026Shares Short
6.46MSharesUpdated Aug 28, 2026Short Ratio
1.85daysvs all stocks
Short % of Shares Outstanding
4.72%vs all stocks
% Held by Insiders
0.33%vs all stocks
% Held by Institutions
114.95%vs all stocks
Total Cash (MRQ)
265.48MUSDvs all stocks (USD)
Total Cash per Share (MRQ)
1.69USDUpdated Aug 28, 2026Total Debt (MRQ)
289.09MUSDvs all stocks (USD)
Total Debt to Equity (MRQ)
0.1371xvs Biotechnology peers
Current Ratio (MRQ)
4.55xvs Biotechnology peers
Book Value per Share (MRQ)
13.32USDUpdated Aug 28, 2026Total Assets
2.56BUSDvs all stocks (USD)
Total Current Assets
608.30MUSDFY2025 · Jun 30, 2025Total Liabilities
639.06MUSDFY2025 · Jun 30, 2025Total Non-current Assets
1.95BUSDFY2025 · Jun 30, 2025Total Non-current Liabilities
463.21MUSDFY2025 · Jun 30, 2025Total Current Liabilities
175.85MUSDFY2025 · Jun 30, 2025Cash & Cash Equivalents
162.19MUSDFY2025 · Jun 30, 2025Other Short-term Investments
0.00USDFY2025 · Jun 30, 2025Accounts Receivable
206.88MUSDFY2025 · Jun 30, 2025Inventory
189.45MUSDFY2025 · Jun 30, 2025Accounts Payable
25.31MUSDFY2025 · Jun 30, 2025Short-term Debt
14.10MUSDFY2025 · Jun 30, 2025Deferred Revenue
32.57MUSDFY2025 · Jun 30, 2025Other Current Liabilities
1.65MUSDFY2025 · Jun 30, 2025Long-term Debt
429.96MUSDFY2025 · Jun 30, 2025Other Non-current Liabilities
27.08MUSDFY2025 · Jun 30, 2025Common Stock (Book)
1.55MUSDFY2025 · Jun 30, 2025Retained Earnings
1.07BUSDFY2025 · Jun 30, 2025Total Shareholders' Equity
1.92BUSDvs all stocks (USD)
52-Week Low
43.20USDUpdated Aug 28, 202652-Week High
72.62USDUpdated Aug 28, 202652-Week Change
32.53%vs all stocks
Beta
1.28xvs all stocks
50-Day MA
70.25USDUpdated Aug 28, 2026200-Day MA
60.62USDUpdated Aug 28, 2026Avg 10-Day Volume
2.45MSharesUpdated Aug 28, 2026Avg 30-Day Volume
3.22MSharesUpdated Aug 28, 2026Diluted EPS (TTM)
1.16USDUpdated Aug 28, 2026Other Income / Expense
-139.72MUSDFY2025 · Jun 30, 20254 interpretations currently present — each is a set of fired observations whose alignment reads as one structural pattern. Click an observation to see the numbers behind it.
Screen for these patternsIs this company financially stable?
Diagnostic
Goodwill-Heavy Equity
Equity looks heavy for the industry, but much of it is goodwill from past acquisitions.
Reads
MRQ Cash Elevated Relative To Total Debt With EBITDA And FCF Elevated Relative To Total Liabilities
Cash covers most of its debt, with earnings high against its liabilities.
Reads
How does this company use capital?
Industry-Benchmarked ROA and Margin Elevated
Returns and margins have sat in the top of its industry across five years.
Reads
How is this stock valued?
High Retained Earnings With Profitability And Equity
Profits kept in the business fund much of what it owns, after five straight profitable years.
Reads
An interpretation is present only while every observation it reads stays fired (score ≥ 70). It describes what the aligned readings show — never a verdict, never a prediction.
Shared structure with peers — never a ranking.
Relationships view
Structural observations derived from financial data, industry benchmarks, and supply chain position.
Financial Health
Altman Z-Score 12.07: safe zoneNotable
Altman Z-Score: 12.07
High earnings qualityNotable
Earnings Quality Score: 0.97
Supply Chain
Upstream position: supplies 6 industries, depends on 3Notable
Outgoing: 6.00Incoming: 3.00
Scale
Market cap is $11.36B, above the global median of $1.18BNotable
Market cap (USD): 11,364,617,707Global Median: 1,179,398,897.704
Revenue is $1.22B, above the global median of $534.05MNotable
Revenue (USD): 1,215,038,976Global Median: 534,052,387.958
Levered free cash flow is $229.65M, above the global median of $19.19MNotable
Levered free cash flow (USD): 229,653,120Global Median: 19,189,974.917
Companies that share the same coordination system — how they create, deliver, or capture value.
Recordati Industria Chimica e Farmaceutica S.p.A.
Tier 1ProductionApproval-Gated PipelineRuleFlow
Haisco Pharmaceutical Group Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRuleFlow
Sichuan Kelun Pharmaceutical Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRuleFlow
Bio-Rad Laboratories Inc.
Tier 1ProductionApproval-Gated PipelineRuleFlow
Dr. Reddy's Laboratories Ltd.
Tier 1ProductionApproval-Gated PipelineRuleFlow
Shanghai Fosun Pharmaceutical Group Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRuleFlow
Asymchem Laboratories (Tianjin) Co., Ltd.
Tier 1ProductionApproval-Gated PipelineFlowRule
Pharmaron Beijing Co., Ltd.
Tier 1ProductionApproval-Gated PipelineSenseMakingFlow
Masimo Corporation
Tier 1ProductionApproval-Gated PipelineRuleFlow
Aurobindo Pharma Ltd.
Tier 1ProductionApproval-Gated PipelineRuleFlow
Companies that share active interpretations — structural patterns currently present in both stocks.
Yealink Network Technology Co., Ltd.
3 interpretationsMRQ Cash Elevated Relative To Total Debt With EBITDA And FCF Elevated Relative To Total LiabilitiesHigh Retained Earnings With Profitability And EquityIndustry-Benchmarked ROA and Margin Elevated
Regeneron Pharmaceuticals, Inc.
3 interpretationsMRQ Cash Elevated Relative To Total Debt With EBITDA And FCF Elevated Relative To Total LiabilitiesHigh Retained Earnings With Profitability And EquityIndustry-Benchmarked ROA and Margin Elevated
Watts Water Technologies Inc.
4 interpretationsMRQ Cash Elevated Relative To Total Debt With EBITDA And FCF Elevated Relative To Total LiabilitiesHigh Retained Earnings With Profitability And EquityLong Dividend Streak With Three-Year FCF CoverageIndustry-Benchmarked ROA and Margin Elevated